{
    "info": {
        "nct_id": "NCT06756308",
        "official_title": "A Phase 2 Study of Enasidenib in IDH2-Mutant Angioimmunoblastic T-Cell Lymphoma",
        "inclusion_criteria": "* Pathologically-confirmed AITL at the enrolling institution, with confirmed IDH2 mutation (by MSK ddPCR). For R/R patients, disease must have relapsed or progressed after at least one systemic therapy, diagnostic tumor samples have at least 5% tumor. i) IDH2 hotspot mutation confirmed by CAP/CLIA-certified NGS testing panel. Only cases with confirmed mutations detected >1% VAF will be eligible.\n* Age ≥18 years at time of enrollment Previous systemic anti-cancer therapy for AITL must have been discontinued at least 2 weeks or 5 half-lives (whichever is longer) prior to treatment.\n\n  i) ii) See section 6.2 Subject Exclusion Criteria for guidelines regarding adjuvant and maintenance therapy for prior malignancy. Patients who have received localized RT as part of their immediate prior therapy may be allowed to enroll with shorter washout period after discussion with the MSKCC Principal Investigator ii) Patients who have received localized RT as part of their immediate prior therapy may be allowed to enroll with shorter washout period after discussion with the MSKCC Principal Investigator iii) Systemic corticosteroids must be tapered to 25 mg/day prednisone (or equivalent) upon start of investigational treatment iv) 4) 5) 6) 7) 8) 9) Topical steroids for treating cutaneous involvement of AITL is permitted Performance status, as assessed in the ECOG grading system, ≤2 Laboratory criteria (use of GCSF and/or blood product transfusions to reach eligibility criteria must be discussed with the MSK PI on a case-by-case basis):\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "-",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "i) ii) See section 6.2 Subject Exclusion Criteria for guidelines regarding adjuvant and maintenance therapy for prior malignancy. Patients who have received localized RT as part of their immediate prior therapy may be allowed to enroll with shorter washout period after discussion with the MSKCC Principal Investigator ii) Patients who have received localized RT as part of their immediate prior therapy may be allowed to enroll with shorter washout period after discussion with the MSKCC Principal Investigator iii) Systemic corticosteroids must be tapered to 25 mg/day prednisone (or equivalent) upon start of investigational treatment iv) 4) 5) 6) 7) 8) 9) Topical steroids for treating cutaneous involvement of AITL is permitted Performance status, as assessed in the ECOG grading system, ≤2 Laboratory criteria (use of GCSF and/or blood product transfusions to reach eligibility criteria must be discussed with the MSK PI on a case-by-case basis):",
                "criterions": [
                    {
                        "exact_snippets": "Patients who have received localized RT as part of their immediate prior therapy may be allowed to enroll with shorter washout period after discussion with the MSKCC Principal Investigator",
                        "criterion": "prior localized radiotherapy (RT)",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": "immediate prior therapy"
                        }
                    },
                    {
                        "exact_snippets": "Patients who have received localized RT as part of their immediate prior therapy may be allowed to enroll with shorter washout period after discussion with the MSKCC Principal Investigator",
                        "criterion": "prior localized radiotherapy (RT)",
                        "requirement": {
                            "requirement_type": "washout period",
                            "expected_value": "shorter than standard, allowed after discussion with MSKCC Principal Investigator"
                        }
                    },
                    {
                        "exact_snippets": "Systemic corticosteroids must be tapered to 25 mg/day prednisone (or equivalent) upon start of investigational treatment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 25,
                                "unit": "mg/day prednisone (or equivalent)"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Systemic corticosteroids must be tapered to 25 mg/day prednisone (or equivalent) upon start of investigational treatment",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "upon start of investigational treatment"
                        }
                    },
                    {
                        "exact_snippets": "Topical steroids for treating cutaneous involvement of AITL is permitted",
                        "criterion": "topical steroid use for cutaneous AITL",
                        "requirement": {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Performance status, as assessed in the ECOG grading system, ≤2",
                        "criterion": "performance status (ECOG)",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "ECOG"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Patients who have received localized RT as part of their immediate prior therapy may be allowed to enroll with shorter washout period after discussion with the MSKCC Principal Investigator",
                                "criterion": "prior localized radiotherapy (RT)",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": "immediate prior therapy"
                                }
                            },
                            {
                                "exact_snippets": "Patients who have received localized RT as part of their immediate prior therapy may be allowed to enroll with shorter washout period after discussion with the MSKCC Principal Investigator",
                                "criterion": "prior localized radiotherapy (RT)",
                                "requirement": {
                                    "requirement_type": "washout period",
                                    "expected_value": "shorter than standard, allowed after discussion with MSKCC Principal Investigator"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Systemic corticosteroids must be tapered to 25 mg/day prednisone (or equivalent) upon start of investigational treatment",
                                "criterion": "systemic corticosteroid use",
                                "requirement": {
                                    "requirement_type": "dosage",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 25,
                                        "unit": "mg/day prednisone (or equivalent)"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Systemic corticosteroids must be tapered to 25 mg/day prednisone (or equivalent) upon start of investigational treatment",
                                "criterion": "systemic corticosteroid use",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": "upon start of investigational treatment"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Topical steroids for treating cutaneous involvement of AITL is permitted",
                        "criterion": "topical steroid use for cutaneous AITL",
                        "requirement": {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Performance status, as assessed in the ECOG grading system, ≤2",
                        "criterion": "performance status (ECOG)",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "ECOG"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "-",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Pathologically-confirmed AITL at the enrolling institution, with confirmed IDH2 mutation (by MSK ddPCR). For R/R patients, disease must have relapsed or progressed after at least one systemic therapy, diagnostic tumor samples have at least 5% tumor. i) IDH2 hotspot mutation confirmed by CAP/CLIA-certified NGS testing panel. Only cases with confirmed mutations detected >1% VAF will be eligible.",
                "criterions": [
                    {
                        "exact_snippets": "Pathologically-confirmed AITL at the enrolling institution",
                        "criterion": "AITL diagnosis",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathological confirmation at enrolling institution"
                        }
                    },
                    {
                        "exact_snippets": "confirmed IDH2 mutation (by MSK ddPCR) ... IDH2 hotspot mutation confirmed by CAP/CLIA-certified NGS testing panel",
                        "criterion": "IDH2 mutation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "confirmed IDH2 mutation (by MSK ddPCR) ... IDH2 hotspot mutation confirmed by CAP/CLIA-certified NGS testing panel",
                        "criterion": "IDH2 mutation",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "MSK ddPCR",
                                "CAP/CLIA-certified NGS testing panel"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "For R/R patients, disease must have relapsed or progressed after at least one systemic therapy",
                        "criterion": "disease status (relapsed/refractory)",
                        "requirement": {
                            "requirement_type": "relapse/progression after systemic therapy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "For R/R patients, disease must have relapsed or progressed after at least one systemic therapy",
                        "criterion": "disease status (relapsed/refractory)",
                        "requirement": {
                            "requirement_type": "minimum number of prior systemic therapies",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "systemic therapy"
                            }
                        }
                    },
                    {
                        "exact_snippets": "diagnostic tumor samples have at least 5% tumor",
                        "criterion": "tumor content in diagnostic sample",
                        "requirement": {
                            "requirement_type": "tumor cell percentage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Only cases with confirmed mutations detected >1% VAF will be eligible",
                        "criterion": "IDH2 mutation variant allele frequency (VAF)",
                        "requirement": {
                            "requirement_type": "VAF threshold",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Age ≥18 years at time of enrollment Previous systemic anti-cancer therapy for AITL must have been discontinued at least 2 weeks or 5 half-lives (whichever is longer) prior to treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Age ≥18 years at time of enrollment",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Previous systemic anti-cancer therapy for AITL must have been discontinued at least 2 weeks or 5 half-lives (whichever is longer) prior to treatment.",
                        "criterion": "discontinuation of previous systemic anti-cancer therapy for AITL",
                        "requirement": {
                            "requirement_type": "minimum time since discontinuation",
                            "expected_value": "at least 2 weeks or 5 half-lives (whichever is longer) prior to treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age \u001e18 years at time of enrollment",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Previous systemic anti-cancer therapy for AITL must have been discontinued at least 2 weeks or 5 half-lives (whichever is longer) prior to treatment.",
                        "criterion": "discontinuation of previous systemic anti-cancer therapy for AITL",
                        "requirement": {
                            "requirement_type": "minimum time since discontinuation",
                            "expected_value": "at least 2 weeks or 5 half-lives (whichever is longer) prior to treatment"
                        }
                    }
                ]
            }
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}